178 related articles for article (PubMed ID: 25495414)
1. Retrospective evaluation of the efficacy of first-line treatment of advanced gastric cancer with docetaxel and oxaliplatin.
Mao ZY; Guo XC; Su D; Wang LJ; Zhang TT; Bai L
Cancer Invest; 2015 Jan; 33(1):16-21. PubMed ID: 25495414
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer.
Kim YS; Sym SJ; Park SH; Park I; Hong J; Ahn HK; Park J; Cho EK; Lee WK; Chung M; Lee JH; Shin DB
Cancer Chemother Pharmacol; 2014 Jan; 73(1):163-9. PubMed ID: 24202666
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
Lee JL; Ryu MH; Chang HM; Kim TW; Yook JH; Oh ST; Kim BS; Kim M; Chun YJ; Lee JS; Kang YK
Cancer Chemother Pharmacol; 2008 Apr; 61(4):631-7. PubMed ID: 17520252
[TBL] [Abstract][Full Text] [Related]
7. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S
Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer.
Zhong H; Zhang Y; Ma S; Ying JE; Yang Y; Yong D; Hang X; Sun Q; Zhong B; Wang D
Anticancer Drugs; 2008 Nov; 19(10):1013-8. PubMed ID: 18827567
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of docetaxel- and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients.
Chen L; Shi Y; Yuan J; Wu Q; Han Y; Qin R; Jia B; Wei B; Wei L; Dai G; Jiao S
Med Oncol; 2014 Sep; 31(9):159. PubMed ID: 25119501
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Lopes G; Rosado MF; Negret LM; Rocha-Lima C; Tolba K; Farfan N; Hamilton-Nelson K; Silva O; Roman E
Lung Cancer; 2006 Sep; 53(3):347-53. PubMed ID: 16844257
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients.
Yeh YS; Tsai HL; Ma CJ; Wu DC; Lu CY; Wu IC; Hou MF; Wang JY
Chemotherapy; 2012; 58(5):411-8. PubMed ID: 23306825
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer.
Yang L; Song Y; Zhou AP; Qin Q; Chi Y; Huang J; Wang JW
Chin Med J (Engl); 2013; 126(18):3470-4. PubMed ID: 24034092
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):985-90. PubMed ID: 23995699
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer.
Kondoh C; Takahari D; Shitara K; Mizota A; Nomura M; Yokota T; Ura T; Ito S; Kawai H; Sawaki A; Muro K
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1511-5. PubMed ID: 23064062
[TBL] [Abstract][Full Text] [Related]
19. Docetexal plus S-1 versus oxaliplatin plus S-1 for first-line treatment of patients with advanced gastric cancer: a retrospective study.
Wang M; Wu M; Wang W; Wang Q; Wang Y
Oncol Res Treat; 2014; 37(1-2):24-8. PubMed ID: 24613905
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]